Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The study will investigate whether combination antiretroviral therapy of raltegravir and
3TC/ABC is effective and safe to use in tuberculosis (TB)/HIV co-infected adults receiving
rifabutin-containing, first-line antituberculous treatment.
Hypothesis:Combination antiretroviral therapy of raltegravir and 3TC/ABC and is effective and
safe to use in tuberculosis (TB)/HIV co-infected adults receiving rifabutin-based first-line
antituberculous treatment.